

“Help me control my diabetes early and maintain healthy A1c and weight goals.”

Get an early headstart with

RYBELSUS[®]
semaglutide tablets
A GAME CHANGER. A LIFE CHANGER.

Not a real patient. The images of person depicted are for illustration purposes only. Not a real case profile, depicted profile is for hypothetical purposes only

~ 9/10 PwDs¹ like Varsha are overweight^{2,3}


Varsha, 35

- HbA1c: 8.5%
- BMI: 30 kg/m²
- High BP
- Medication: Metformin BD
- History: Sedentary lifestyle, family history of T2D+CVD,

Not a real patient. The images of person depicted are for illustration purposes only. Not a real case profile, depicted profile is for hypothetical purposes only

Start early to support her journey

Start early with Rybelsus[®] for glycaemic & weight goals



Not a real patient. The images of person depicted are for illustration purposes only. Not a real case profile, depicted profile is for hypothetical purposes only



Benefits of Rybelsus[®]

Major benefits of oral Semaglutide are likely to occur when administered early

- Up to **1.6%** reduction in HbA1c⁴
- Up to **4.3** weight reduction⁴
- <7%, ≤6.5%, <6%** HbA1c targets achieved⁴

Benefits of Lowering **Weight of Diabetes**


- >5%** Lower high BP and glucose levels^{5,6}
- 5%-10%** Prevents diabetes elevated cholesterol, PCOS, fatty liver⁷
- 10%-15%** Reduces heart disease, fatty liver and sleep apnoea⁸
- >15%** Helps in T2DM and reduces CVD-led mortality⁹



Experts talk about an early start with **Rybelsus[®]**

[Click to know more](#)

Early intensive treatment provides sustained glycaemic control^{10,11}



Check out other profiles

- MOHAN'S PROFILE** [Discover more](#)
- VARSHA'S PROFILE** [Discover more](#)
- ABOUT RYBELSUS[®]** [Discover more](#)

Disclaimer: Not a real patient. The images of person depicted are for illustration purposes only. Not a real case profile, depicted profile is for hypothetical purposes only

*Rybelsus[®] Prescribing Information

Abbreviations: HbA1c: Glycated hemoglobin, MAE: Major Adverse Cardiovascular Events, T2D: Type 2 Diabetes, CVD: Cardiovascular disease BP: Blood Pressure, PwDs: People with Diabetes, *oral sema 14 mg vs pbo for both duration ≤1 year, *oral sema 3, 7, or 14 mg respectively

References:

- Borgharkar SS, BMJ Open Diabetes Res Care. 2019 Jul 14;7(1):e000654.
- Andersen A, Knop FK, Vilsbøll T. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs. 2021 Jun;81(9):1003-1030. doi:10.1007/s40265-021-01499-w. Epub 2021 May 8. PMID: 33964002; PMCID: PMC8217049.
- ADA Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47
- Goldenberg R, Aroda V, Bardrum L, et al. Achievement of near-normal HbA1c with early initiation of oral semaglutide: an exploratory subgroup analysis of PIONEER 1. Can J Diabetes. 2021;45(7):528-529. doi: https://doi.org/10.1016/j.cjcd.2021.09.085
- Benaoune et al., Curr Opin Cardiol 2011;26:555-61.
- Sundström J et al. Circulation 2017;135:1577-85
- Look AHEAD Research Group. Lancet Diabetes Endocrinol 2016;4:913-21
- Lean ME et al. Lancet 2018;391:541-51
- Garvey WT et al. Endocr Pract 2016;22(Suppl. 3):1-203.
- Khuntli K, et al. Diab Care 2013;36:3411-7;
- Del Prato S, et al. Int J Clin Pract 2005;59:1345-1355

NOVO NORDISK INDIA PRIVATE LIMITED

Contact us
Plot No.32, 47-50,
ETP Area, Whitefield
Bengaluru 560 066
Phone: +91 80 4030 3200
Fax: +91 80 4112 3518
Mail:
pnrindia@novonordisk.com

Adverse events or product related complaints:
INAgree@novonordisk.com

HELPFUL LINKS

Contact us
COVID-19 information
Extract of Annual Return
Annual Return
CSR Policy

FOLLOW US

LinkedIn
YouTube
Facebook
Twitter

OTHER OFFICES

© Select country